Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2015, Article ID 703457, 4 pages
http://dx.doi.org/10.1155/2015/703457
Case Report

Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation

1Cancer Molecular Diagnostics, St. James’s Hospital, Dublin 8, Ireland
2Department of Haematology, St. James’s Hospital, Dublin 8, Ireland
3Department of Histopathology, St. James’s Hospital, Dublin 8, Ireland

Received 15 June 2015; Revised 17 July 2015; Accepted 22 July 2015

Academic Editor: Ramon Tiu

Copyright © 2015 Stephen E. Langabeer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Tefferi, “Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management,” American Journal of Hematology, vol. 89, no. 9, pp. 915–925, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Rosenthal and R. A. Mesa, “Janus kinase inhibitors for the treatment of myeloproliferative neoplasms,” Expert Opinion on Pharmacotherapy, vol. 15, no. 9, pp. 1265–1276, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Babushok and E. Hexner, “Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?” Current Opinion in Hematology, vol. 21, no. 2, pp. 114–122, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Alchalby, A. Badbaran, T. Zabelina et al., “Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis,” Blood, vol. 116, no. 18, pp. 3572–3581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Panagiota, F. Thol, B. Markus et al., “Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation,” Leukemia, vol. 28, no. 7, pp. 1552–1555, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Kröger, H. Alchalby, E. Klyuchnikov et al., “JAK2-V617F triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation,” Blood, vol. 113, no. 8, pp. 1866–1868, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Lange, A. Edelmann, U. Siebolts et al., “JAK2 p.V617F allele burden in myelo proliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse,” Haematologica, vol. 98, no. 5, pp. 722–728, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Haslam, S. E. Langabeer, K. Molloy, M. F. McMullin, and E. Conneally, “Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation,” British Journal of Haematology, vol. 166, no. 5, pp. 800–802, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Alchalby, A. Badbaran, O. Bock et al., “Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT,” Bone Marrow Transplantation, vol. 45, no. 9, pp. 1404–1407, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Cervantes, B. Dupriez, A. Pereira et al., “New prognostic scoring system for primary myelofibrosis based on a study of the International working group for myelofibrosis research and treatment,” Blood, vol. 113, no. 13, pp. 2895–2901, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Kröger, E. Holler, G. Kobbe et al., “Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation,” Blood, vol. 114, no. 26, pp. 5264–5270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. T. S. Larsen, J. H. Christensen, H. C. Hasselbalch, and N. Pallisgaard, “The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders,” British Journal of Haematology, vol. 136, no. 5, pp. 745–751, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. V. Jovanovic, A. Ivey, A. M. Vannucchi et al., “Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study,” Leukemia, vol. 27, no. 10, pp. 2032–2039, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Haslam, K. M. Molloy, E. Conneally, and S. E. Langabeer, “Evaluation of a JAK2 V617F quantitative PCR to monitor residual disease post-allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms,” Clinical Chemistry and Laboratory Medicine, vol. 52, no. 3, pp. e29–e31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Gupta, A. K. Malone, P. N. Hari et al., “Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research,” Biology of Blood and Marrow Transplantation, vol. 20, no. 1, pp. 89–97, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. N. K. Steckel, M. Koldehoff, M. Ditschkowski, D. W. Beelen, and A. H. Elmaagacli, “Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation,” Transplantation, vol. 83, no. 11, pp. 1518–1520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Kröger, A. Badbaran, E. Holler et al., “Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis,” Blood, vol. 109, no. 3, pp. 1316–1321, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Yoshihara, H. Tamaki, K. Ikegame et al., “Early prediction of extramedullary relapse of leukemia following allogeneic stem cell transplantation using the WT1 transcript assay,” Biology of Blood and Marrow Transplantation, vol. 12, no. 2, p. 86, 2006. View at Publisher · View at Google Scholar
  19. H. Tamaki, S. Yoshihara, T. Fujioka, M. Kawakami, Y. Oka, and H. Ogawa, “Molecular detection of AML1-MTG8-positive cells in peripheral blood from a patient with isolated extramedullary relapse of t(8;21) acute myeloid leukemia,” Leukemia, vol. 23, no. 2, pp. 424–426, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Y. Au, A. Fung, A. K. Lie, K. Y. Lam, C. C. Lam, and Y. L. Kwong, “Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis,” Annals of Hematology, vol. 86, no. 2, pp. 145–147, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. Q. Huang, D. Reddi, P. Chu, D. S. Snyder, and D. D. Weisenburger, “Clinical and pathologic analysis of extramedullary tumors after hematopoietic stem cell transplantation,” Human Pathology, vol. 45, no. 12, pp. 2404–2410, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. Haniffa, B. S. Wilkins, C. Blasdale, and N. B. Simpson, “Cutaneous extramedullary hemopoiesis in chronic myeloproliferative and myelodysplastic disorders,” Journal of the American Academy of Dermatology, vol. 55, supplement 2, pp. S28–S31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. G. R. Fraga and S. K. Caughron, “Cutaneous myelofibrosis with JAK2 V617F mutation: metastasis, not merely extramedullary hematopoiesis!,” The American Journal of Dermatopathology, vol. 32, no. 7, pp. 727–730, 2010. View at Publisher · View at Google Scholar · View at Scopus